Effectiveness of Castration Versus Intravenous Estrogen Therapy in Producing Rapid Endocrine Control of Metastatic Cancer of the Prostate-Reference-Cited by-同舟云学术

Effectiveness of Castration Versus Intravenous Estrogen Therapy in Producing Rapid Endocrine Control of Metastatic Cancer of the Prostate

Published:1985-04 Issue:4 Volume:133 Page:620-621
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Maatman Thomas J.¹,Gupta Manjula K.¹,Montie James E.¹

Affiliation:

1. From the Departments of Urology and Immunopathology, The Cleveland Clinic Foundation, Cleveland, Ohio

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference8 articles.

1. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate;Huggins;Cancer Res.,1941

2. Therapy with orchiectomy or estrogens or both;Brendler;J.A.M.A.,1969

3. Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma;Robinson;Brit. Med. J.,1971

4. Plasma testosterone levels in patients with prostatic carcinoma before and after treatment;Young;J. Urol.,1968

5. Carcinoma of the prostate: early endocrine therapy is best;Spirnak;Sem. Urol.,1983

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review;Frontiers in Endocrinology;2023-02-06

2. Androgen Deprivation Therapy;Chemotherapy and Immunotherapy in Urologic Oncology;2020-09-30

3. Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation;European Journal of Medicinal Chemistry;2020-04

4. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis;Cancer Letters;2018-12

5. Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens;Research and Reports in Urology;2018-02